Loading
Elena Garralda is Director of the Early Drug Development Unit (UITM) at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, one of Europe's largest phase 1 units. Her specialisms are phase 1 trials, immuno-oncology and novel modalities, including bispecific antibodies and antibody-drug conjugates. She runs first-in-human trials of ADCs, bispecifics, cell therapies and immunotherapies. Her papers include the Nature Medicine phase 1 trial of OMO-103, a MYC-targeting agent, in solid tumours, a study of the cytokine agent NIZ985 alone and with an anti-PD-1 agent in advanced solid tumours or lymphoma, and the ARROW phase 1/2 study of pralsetinib in RET fusion-positive non-small-cell lung cancer. Her publications are listed on PubMed.
Shares Vall d'Hebron University Hospital / VHIO, Antibody-drug conjugate (ADC).
Shares Bispecific antibodies, Antibody-drug conjugate (ADC).
Shares Bispecific antibodies, Antibody-drug conjugate (ADC).
Shares Bispecific antibodies, Antibody-drug conjugate (ADC).
Shares Bispecific antibodies, Antibody-drug conjugate (ADC).
Shares Vall d'Hebron University Hospital / VHIO, Antibody-drug conjugate (ADC).
Shares Bispecific antibodies, Antibody-drug conjugate (ADC).
Shares Bispecific antibodies, Antibody-drug conjugate (ADC).